Net Deals Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. Novartis Ag (NVS) Q2 2024 Earnings Call Transcript - AOL

    www.aol.com/novartis-ag-nvs-q2-2024-204516120.html

    Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024, 8:00 a.m. ET. ... Good morning, and good afternoon, and welcome to the Novartis Q2 2024 results release conference call and live webcast ...

  3. Novartis lifts profit forecast for second time on Cosentyx ...

    www.aol.com/news/novartis-raises-2024-profit...

    Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart failure treatment Entresto and arthritis ...

  4. Novartis raises sales growth target to 5% a year through 2027

    www.aol.com/news/novartis-lifts-sales-growth...

    The breast cancer drug was shown this year to help a wider patient group in a study, a major win for CEO Vas Narasimhan, and Novartis said it saw peak an Novartis raises sales growth target to 5% ...

  5. List of largest biomedical companies by revenue - Wikipedia

    en.wikipedia.org/wiki/List_of_largest_biomedical...

    List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...

  6. Novartis - Wikipedia

    en.wikipedia.org/wiki/Novartis

    Novartis AG. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...

  7. Nilotinib - Wikipedia

    en.wikipedia.org/wiki/Nilotinib

    Nilotinib is a Bcr-Abl tyrosine kinase inhibitor and works by interfering with signalling within the cancer cell. [ 5] Nilotinib was approved for medical use in the United States in 2007. [ 5] It is on the World Health Organization's List of Essential Medicines. [ 6] It is approved as a generic medication.

  8. Novartis in advanced talks to buy Cytokinetics- source - AOL

    www.aol.com/news/novartis-advanced-talks-buy...

    (Reuters) -Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

  9. Novartis misses Q4 profit expectations as costs disappoint - AOL

    www.aol.com/news/novartis-misses-q4-profit...

    Novartis also extended its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings. It had previously projected that pace of growth through 2027.